Japan-based Sosei Group Corp has entered a global collaboration and licencing agreement with GlaxoSmithKline Plc to discover small molecule agonists of a G protein-coupled receptor (GPCR) associated with inflammatory bowel disease and other gastrointestinal immune disorders. It will use technology developed by Heptares Therapeutics, a UK company it acquired in 2015. The deal is the newest collaboration for Sosei, which is using the Heptares’ structure-based drug design platform to grow its business.
